Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2009-08-25
2010-12-21
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024300, C536S024330
Reexamination Certificate
active
07855283
ABSTRACT:
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Arenaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment ofArenavirusinfection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 19 nucleotide region of the 5′-terminal regions of the viral RNA, viral complementary RNA and/or mRNA identified by SEQ ID NO:1.
REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5521063 (1996-05-01), Summerton et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5698685 (1997-12-01), Summerton et al.
patent: 6365351 (2002-04-01), Iversen
patent: 6677153 (2004-01-01), Iversen
patent: 6784291 (2004-08-01), Iversen et al.
patent: 6828105 (2004-12-01), Stein et al.
patent: 6841542 (2005-01-01), Bartelmez et al.
patent: 7049431 (2006-05-01), Iversen et al.
patent: 7094765 (2006-08-01), Iversen et al.
patent: 91/09073 (1991-06-01), None
patent: 03/025139 (2003-03-01), None
Agrawal et al., Molecular Medicine Today, 2000 vol. 6:72-81.
Agrawal et al., Proc Natl Acad Sci U S A., 87(4):1401-5 (1990).
Barton et al. “Lymphocytic choriomeningitis virus:emerging fetal teratogen.” Am J Obstet Gynecol, 187(6):1715-6 (2002).
Blommers et al., Nucleic Acids Res., 22(20):4187-94 (1994).
Bonham et al., Nucleic Acids Res., 23(7):1197-203 (1995).
Boudvillain et al., Biochemistry 36(10):2925-31 (1997).
Branch, TIBS, 1998 vol. 23:45-50.
Cross et al., “Solution structure of an RNA×DNA hybrid duplex containing a 3′-thioformacetal linker and an RNA A-tract,” Biochemistry, 36(14): 4096-107 (1997).
Ding, et al., Nucleic Acids Res 24(2):354-60, (1996).
Egholm et al., “PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules.” Nature, 365(6446): 566-8 (1993).
Felgner et al., PNAS, 84(21): 7413-7 (1987).
Gait et al., J. Chem. Soc., 0(14):1684-1686 (1974).
Gee et al., Antisense Nucleic Acid Drug Dev 8(2):103-11 (1998).
Gewirtz et al. Proc. Natl. Acad. Sci., 1996 vol. 93:3161-3163.
Iversen et al., “Non-Invasive Method for Detecting Target RNA,” U.S. Appl. No. 09/736,920, filed Dec. 13, 2000, 64 pages.
Lesnikowski et al., “Octa(thymidine methanephosphonates) of partially defined stereochemistry: synthesis and effect of chirality at phosphorus on binding to pentadecadeoxyriboadenylic acid.” Nucleic Acids Res., 18(8): 2109-15 (1990).
Mertes et al. (1969). “Synthesis of carbonate analogs of dinucleosides. 3′-Thymidinyl 5′-thymidinyl carbonate, 3′-thymidinyl 5′-(5-fluoro-2′-deoxyuridinyl) carbonate, and 3′-(5-fluoro-2′-deoxyuridinyl) 5′-thymidinyl carbonate.” J Med Chem., 12(1): 154-7.
Meyer et al., Curr. Top. Microbiol. Immunol., 262:139-157 (2002).
Moulton et al., Bioconjug Chem 15(2): 290-9 (2004).
Nelson et al., “Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.” Bioconjug Chem., 16(4): 959-66 (2005).
Neuman et al. Journal of Virology, 2005 vol. 79:9665-9676.
Nielsen, Gene Therapy, 2005 vol. 12:956-957.
Phillips, “Antisense Therapeutics: A Promise Waiting to be Fulfilled,” Methods in Molecular Medicine, 106:3-10 (2005).
Polyak et al., Journal of Virology, 69(5):3211-3215 (1995).
Schiavone et al., Current Pharmaceutical Design, 20:769-784 (2004).
Summerton, “Morpholino antisense oligomers: design, preparation, and properties.”, Antisense Nucleic Acid Drug Dev., 7(3): 187-95 (1997).
Tamm et al., The Lancet, 2001 vol. 358:489-497.
AVI BioPharma Inc.
Gibbs Terra Cotta
McGarry Sean
Seed IP Law Group PLLC
LandOfFree
Antisense antiviral compound and method for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense antiviral compound and method for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense antiviral compound and method for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201539